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016 Elsevier B.V. All rigAbstract Objective: To determine if serum cardiac troponin I (cTnI) concentra-
tion distinguishes between cardiogenic syncope and collapsing dogs presenting with
either generalized epileptic seizures (both with and without cardiac disease) or va-
sovagal syncope.
Animals: Seventy-nine prospectively recruited dogs, grouped according to aetiol-
ogy of collapse: generalized epileptic seizures (group E), cardiogenic syncope
(group C), dogs with both epileptic seizures and cardiac disease (group B), vasova-
gal syncope (group V) or unclassified (group U).
Methods: Most patients had ECG (n ¼ 78), echocardiography (n ¼ 78) and BP mea-
surement (n ¼ 74) performed. Dogs with a history of intoxications, trauma, evi-
dence of metabolic disorders or renal insufficiency (based on serum creatinine
concentrations >150 mmol/L and urine specific gravity <1.030) were excluded. Ser-
um cTnI concentrations were measured and compared between groups using non-
parametric statistical methods. Multivariable regression analysis investigated fac-
tors associated with cTnI. Receiver operator characteristic curve analysis examined
whether cTnI could identify cardiogenic syncope.rdiology.com (E. Dutton).
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ANOVA analysis of varianc
BP blood pressure
CSF cerebrospinal fluid
cTnI cardiac troponin I
GA general anaesthes
Group B group with both ca
seizures
Group C group with cardiog
Group E group with epileps
Group U group in which no
was reached (uncl
Group V group with vasova
MRI magnetic resonanc
ROC receiver operator
SE status epilepticus
SUDEP sudden unexpec
epilepsy
TLOC transient loss of c
USG urine specific gravResults: Median cTnI concentrations were higher in group C than E (cTnI: 0.165
[0.02e27.41] vs. 0.03 [0.01e1.92] ng/mL; p<0.05). Regression analysis found that
serum cTnI concentrations decreased with increasing time from collapse (p¼0.015)
and increased with increasing creatinine concentration (p¼0.028). Serum cTnI diag-
nosed cardiogenic syncope with a sensitivity of 75% and specificity of 80%.
Conclusions: Serum cTnI concentrations were significantly different between
groups C and E. However, due to the overlap in cTnI concentrations between groups
cTnI, measurement in an individual is not optimally discriminatory to differentiate
cardiogenic syncope from collapse with generalized epileptic seizures (both with
and without cardiac disease) or vasovagal syncope.
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Veterinary Internal Medicine Research abstract C-29.Introduction
The two major mechanisms of collapse with tran-
sient loss of consciousness (TLOC) are global cer-
ebral hypoperfusion leading to syncope, and
asynchronous discharge of cerebral neurons caus-
ing a seizure. Syncope and seizures can mimic one
another in veterinary patients [1e3]. In human
patients, this can also occur, with a consequent
high rate of misdiagnosis, particularly as clinical
examination on affected patients is often unre-
markable at presentation [4e11]. Examples of
disorders which may lead to seizure activity and
can be confused with syncope include idiopathic
epilepsy, intracranial disease, encephalopathies
and metabolic disorders such as hypocalcaemia,
hypoxia or hypoglycaemia. In human patients,studies suggest that one in four patients with
‘epilepsy’ may be misdiagnosed [4e8].
In veterinary medicine, published case reports
illustrate the challenges of differentiating syncope
from seizures [1,3]. Structural cardiac disease and
arrhythmias (with or without underlying structural
cardiac disease) can cause syncope [2,12]. Meth-
ods for differentiating benign causes of weakness
and fainting from malignant cardiac arrhythmias,
which may degenerate into ventricular fibrillation
or cardiac arrest, are clinically important but
currently relatively limited. Clinicians are often
reliant on an incomplete medical history.
One cardiac biomarker, cardiac troponin I (cTnI),
is useful for detecting cardiac myocyte damage [13]
and is easy to sample. Increased circulating troponin
concentrations have been associated with both car-
diac [14,15] and non-cardiac conditions [16e22].
Studies in humans show that epileptic patients with
generalized toniceclonic seizures do not have raised
circulating cTnI concentrations [23e26]. However,
increased troponin concentrations may occur with
more severe seizures, such as status epilepticus (SE),
possibly due to seizure-associated catecholamine
release causing tachyarrhythmias, coronary ischae-
mia and thereby myocardial injury [27]. There is
little published information on the association of
serum cTnI concentration with naturally occurring
seizures in dogs, other than single case reports [3,28]
and an oral presentation.e It is important to gain
information regarding cTnI measurements following
syncope or seizures to enable correct interpretation
of data.
There are no data available regarding the clinical
utility of serum cTnI for differentiating cardiac
causes of syncope from seizures in dogs. Circulating
Cardiac troponin in syncope and seizures 3cTnI concentrations are frequently increased in dogs
with underlying heart disease and arrhythmias
[14,15,29e32] and therefore would be expected to
be higher in dogs with cardiogenic syncope. There
may be a role for cTnI in the evaluation and diagnosis
of dogs collapsing with TLOC.
The aim of the study was to examine the clinical
utility of serum cTnI for differentiation of cardio-
genic syncope from collapsing dogs with either
epileptic seizures (with and without cardiac dis-
ease) or vasovagal syncope. It was hypothesized
that dogs with cardiac syncope would have higher
troponin concentrations than collapsing dogs with
seizures or other non-cardiac causes.f Accredited for analytical testing BS ISO/IEC 17025:2005.
g Access Systems AccuTnI Assay, Beckman Coulter Inc, Full-
erton, CA. The AccuTnI assay uses two mouse-derived mono-
clonal antibodies directed against the 24e40 and 41e49 amino
acid sequences of cTnI.
h Vet-MR Grande; Esaote, Florence, Italy.
i The system used for the 24 h Holter recordings was the
Lifecard CF digital Holter recorder (Spacelabs Healthcare,
Issaquah, WA). The Holter analysis was performed using
Spacelabs Pathfinder software.Animals, materials and methods
The study protocol was approved by the University
of Cambridge and University of Liverpool ethical
review committees. Owners provided informed
written consent before participation of their dogs
in the study.
Dogs with episodes of collapse with TLOC were
prospectively and consecutively recruited at three
referral centres between February 2011 and May
2013. The major inclusion criterion was the history
of a collapsing episode, involving TLOC, within
seven days of presentation. Dogs were eligible for
inclusion whether or not they had received prior
medication. Full history was taken and clinical
examination performed, in particular evaluating
for the presence of a murmur or arrhythmia. Dogs
undergoing investigations for suspected seizures
had full neurological examination recorded. The
following were also recorded: breed, age (years),
gender (male/female), neutered status (yes/no),
body weight (kilograms), time since collapse (the
length of time, in hours, between the collapse and
the time at which blood samples were taken on
presentation), any medications being currently
administered (yes/no). For patients with seizures,
the following were also recorded: number of
seizures during the seven days before presentation
(low ¼ 1e2 seizures; medium ¼ 3e5 seizures;
high ¼ 6 or more seizures) and seizure length in
minutes (if more than one seizure had occurred,
then average seizure length was recorded).
Complete blood count, serum biochemistry and
electrolytesweremeasured to screen for concurrent
and causative disease in all the patients. The labo-
ratories were blinded to patient history. Fasting
blood samples for measurement of creatinine con-
centration (mmol/L) were collected and analysed
within 24 h. Blood samples for the troponin assay
were collected into 1-mL plain tubes from all dogs.Plain tube samples were separated by centrifugation
immediately after clotting. The serumwas stored for
up to 12 h at 18 C then transported on ice to a
commercial laboratory (IDEXX Laboratories,f
Wetherby) for analysis. Before analysis, the frozen
serum was allowed to thaw slowly at room temper-
ature. Concentrations of cTnI weremeasured using a
two-site sandwich immunoassayg to detect free and
complexed troponin. The use of this assay has been
reported [33e35] and validated [36] previously for
canine samples. The laboratory reference range
is  0.07 ng/mL. The assay’s lower limit of
detection is 0.01 ng/mL. Dogs were assessed for
cardiac disease on the basis of clinical examination,
BP, electrocardiography (ECG) and echocardiog-
raphy. For patients with seizures, cardiac inves-
tigations were always performed before general
anaesthesia (GA), except when difficult to control
patients arrived in SE. Status epilepticus patients
had cardiac investigations and repeat thoracic aus-
cultation delayed until 24 h following recovery from
anaesthesia.
Dogs with suspected seizures underwent neuro-
imaging. Magnetic resonance imaging (MRI) scansh
with gadolinium contrast were obtained in three
planes of orientation (dorsal, sagittal and trans-
verse) under GA. Pre-contrast and post-contrast T1-
weighted and T2-weighted images were acquired. In
some patients, additional sequences (pre-contrast
and post-contrast FLAIR, gradient echo T2* and STIR)
were carried out to better define the underlying
brain pathology. In dogs without suspected raised
intracranial pressure, cisternal cerebrospinal fluid
(CSF) analyses were performed for diagnosis. CSF
samples were chilled at 4 C up to 12 h before
transportation at ambient temperature to a com-
mercial laboratory (Carmichael Torrence Diagnostic
Services Ltd,W. Yorks.) for analysis. Additional tests,
such as Toxoplasma and Neospora serology, were
performed according to the judgement of the
attending clinician.
If an arrhythmia was identified or suspected as a
cause of collapse, patients underwent 24 h ambu-
latory ECG recording (Holter monitoring).i Holter
diaries were kept by owners or veterinary staff
4 E. Dutton et al.detailing timings of activities such as exercise,
sleep or collapse. Suspected (neurally mediated)
vasovagal patients were definitively diagnosed by
characteristic ECG changes obtained at the time of
collapse, i.e. sinus tachycardia immediately fol-
lowed by bradycardia and sinus pauses, consistent
with the cardio-inhibitory form of neurocardiogenic
syncope [12,37]. Vasovagal patients had no echo-
cardiographic evidence of structural cardiac dis-
ease which could cause the collapse episodes. In
patients for whom congestive heart failure or res-
piratory pathology was suspected, thoracic radio-
graphs (lateral and dorsoventral views) were
obtained. Abdominal ultrasound and blood tests to
exclude infectious causes of myocarditisj were
offered in dogs with ventricular tachycardia, raised
serum troponin concentrations and no detectable
structural cardiac disease. Systolic BP (mmHg) using
a Doppler devicek was measured from the meta-
carpal artery according to protocol [38].
Electrocardiographywas performed by the use of
a routine six-lead ECG machine.l The six limb leads
were recorded simultaneously for a minimum of 20
consecutive RR intervals, at a paper speed of
50 mm/s, gain of 10 mm/mV. Patients underwent
full standard echocardiographic examination with-
out sedation, according to published recom-
mendations [39] using various phased array probes
(1.5e11 MHz), as appropriate for the patient, with
harmonic imaging.m An ECG was recorded simulta-
neously and full M-mode, colour and spectral Dop-
pler studies were recorded and analysed to reach an
echocardiographic diagnosis in each case. For each
variable, the mean of three measurements was
calculated from consecutive cardiac cycles.
Definitive diagnosis of the cause of seizures was
made by evaluation of all contributing evidence.
Dogs were diagnosed with idiopathic epilepsy if
they were younger than six years old at seizure
onset, had recurrent seizures and were normal on
interictal neurological and laboratory examination.
They had to have no evidence of neurological dis-
ease, other than seizures, during their lives. Thisj Anaplasma phagocytophilum antibody, Bartonella henselae
antibody, Borrelia burgdorferi antibody, Ehrlichia canis anti-
body, Toxoplasma gondii IgM and IgG, Neospora caninum
serology, Distemper IgG titre. Carmichael Torrence Diagnostic
Services Ltd, W Yorks, UK.
k CAT Doppler BP Kit, Thames Medical, West Sussex, UK or
Parks Model 811-B Doppler device, Aloha, Oregon.
l Esaote P80 Power, Esaote, Florence, Italy or Seca CT8000P
ECG, Imotek International Ltd, Huntingdon, Cambridgeshire,
UK.
m Esaote Piemedical MyLab 40 Vet, Esaote, Florence, Italy or
Vivid S6 echocardiography machines GE Medical Systems,
Wauwatosa, WI.was further supported by normal results of CSF
analyses and advanced imaging (MRI) with gadoli-
nium contrast. Brain tumour was diagnosed with
advanced imaging (MRI) and meningoencephalitis
diagnosis based on MRI and CSF results. Cluster
seizures were defined as two or more seizures
occurring within a 24 h period in which the patient
regained consciousness between seizures [40].
Dogs were grouped according to aetiology of
collapse (Fig. 1): generalized epileptic seizures
with no evidence of cardiac disease (group E),
cardiogenic syncope with no evidence of neuro-
logical disease (group C), dogs with both general-
ized seizures and cardiac disease (group B),
vasovagal syncope (group V) or unclassified (group
U), for which the cause of collapse could not be
reliably ascribed to either cardiac or neurological
disease, or for which a diagnosis was not reached.
Group E had to be free of cardiac disease based on
examination, BP, ECG and echocardiography.
Dogs collapsing due to trauma or metabolic dis-
orders were excluded. Patients with a history of
intoxications or renal insufficiency were excluded
(based on serum creatinine concentrations
exceeding the upper limit of the laboratory refer-
ence range [>150 mmol/L] and USG measurement
[<1.030]). A flow chart giving numbers of dogs
undergoing specific investigations is shown (Fig. 2).
Statistical analysis
Results were analysed using commercially available
software.n Data were assessed graphically for nor-
mality and by the Kolmogorov Smirnov test. Most
data were not normally distributed, so descriptive
data were given as median (range). Age distribution,
body weights, concentrations of creatinine and cTnI
of the groups were compared. For comparison
between groups, the one-way ANOVA test was
applied if data were normally distributed, with
multiple pairwise testing by the HolmeSidak test.
For non-normally distributed data, the Krus-
kaleWallis ANOVA on ranks was applied, with mul-
tiple pairwise testing by the Dunn’s method. To
compare categorical data, the chi-squared test was
used to assess the difference of proportions of sex
and neutered status between the various groups.
The cTnI data (n ¼ 66 observations) were log
transformed for the regression analysis to achieve a
normal distribution. To determine which variables
were significantly associated with the measuredn SigmaPlot 12 software (Systat Software Inc, London, UK),
Minitab (version 16.2.3), Minitab Ltd., Coventry, UK and STATA
14 (StataCorp LP, College Station, Texas, USA).
Figure 1 Flow chart depicting group categorization of dogs included in the study.
Cardiac troponin in syncope and seizures 5troponin concentrations, univariable regression was
performed. A multivariable backwards stepwise lin-
ear regression analysis was then performed to fur-
ther explain the variation in troponin values, with
themodel being initially populatedwith all availableFigure 2 Flow chart depicting investigations pvariables. The stepwise procedure was as follows: i)
if removal of one or more variables was associated
with a p value of >0.2, then the variable with the
largest associated p value was discarded; ii) if
inclusion of any of the discarded variables waserformed according to suspected diagnosis.
6 E. Dutton et al.associated with a p value of<0.05, then the variable
with the smallest associated p value was added back
into the model; iii) steps i) and ii) were repeated
until no further variables could be added or dis-
carded. Variables examined were serum creatinine
concentration (mmol/L), disease group, age (years),
gender (male or female), neutered status (entered
as binary variables yes or no), bodyweight (kg), time
since collapse to blood sampling (hours), medication
(being administered at, or shortly before, pre-
sentation), systolic BP (mmHg). The chosen regres-
sion model was re-run after removing any variables
with non-significant coefficients (p>0.05) as judged
by their Wald statistics, and the effect of removing
these variables was assessed. For the purpose of the
analysis, samples in which cTnI concentrations were
below limit of detection of the assaywere ascribed a
value of 0.01 ng/mL. For all statistical comparisons,
a P value of <0.05 was accepted as statistically
significant.
Receiver operator characteristic (ROC) curve
analysis was used to determine the ability of cTnI
concentration to discriminate between cardiac
and non-cardiac causes of collapse. Area under
curve and 95% confidence intervals of the ROC
analysis for cTnI were calculated. Visual exami-
nation of the ROC curves was used to select cut-off
values considered to provide an optimal combina-
tion of sensitivity and specificity. The positive and
negative predictive values were calculated,
assuming the prevalence of cardiogenic syncope
was 30%, i.e. the same as we found in this study.Results
Seventy-nine dogs were enrolled in the study and
grouped according to aetiology of collapse with
TLOC (Fig. 1). Breed and signalment are shown in
Table 1. The boxer was the most represented of
the pedigree breeds (n ¼ 10). There were sig-
nificant differences in age and time since collapse
between the groups (Table 1).
The majority of dogs had ECG (n ¼ 78), echo-
cardiographic examination (n ¼ 78) and BP (n ¼ 74)
performed. One patient (3.8 years of age) with
generalized epileptic seizures (group E) had no BP,
ECG or echocardiographic examination performed,
but had no murmur or arrhythmia on cardiac aus-
cultation. The troponin concentration for this
patient was within the laboratory reference range.
There were five BP readings not recorded. Group E
comprised 27 dogs with idiopathic epilepsy, two
with brain tumours (suspected meningioma and
suspected glioma) and one with necrotizing
meningoencephalitis. Five of the 30 group E dogshad cluster seizures. One dog in group E was sus-
pected to have exercise-induced epilepsy. This
case has been described previously [3]. Three
epileptic patients had SE during the 24 h before
presentation, only one requiring GA for seizure
control. In group E, all but one dog were unre-
markable on ECG and echocardiographic exami-
nation. The abnormality detected (mild left
ventricular dilation) was attributed to brady-
cardia. Four of the five patients with cluster seiz-
ures were ranked as having a high number of
seizures. All three SE patients were ranked as high.
Group C (cardiogenic syncope) comprised 14
dogs with arrhythmias (six without and eight with
underlying structural heart disease detected on
echocardiography), three dogs with neoplastic
pericardial effusion and cardiac tamponade, one
with cardiac neoplasia causing secondary right
ventricular outflow tract obstruction, one with
myxomatous degeneration of the mitral valve,
left-sided congestive heart failure and systolic
pulmonary hypertension and one dog with dilated
cardiomyopathy. In group B (dogs with both epi-
leptic seizures and cardiac disease), all nine were
believed to have collapsed as a result of epilepsy
and not cardiac disease. In group V (vasovagal
syncope), only two of the seven dogs were defini-
tively diagnosed based on history and Holter
analysis. The remaining five had suspected vaso-
vagal syncope (based on typical history, breed or
Holter analysis). There were 13 dogs for whom no
diagnosis was reached (group U).
The length of time between the collapse and
blood samplingwas recorded in each case apart from
one group U dog (Table 1). Nine group C patients
were receiving medication at, or shortly prior to,
presentation (Table 1). These included furosemide,
benazepril, pimobendan, lidocaine, sotalol and
digoxin. In group E, 18 patients were taking anti-
convulsants at presentation. These included pheno-
barbitone, levetiracetam, potassium bromide,
gabapentin and diazepam. Other medications
included oral antibiotics (n ¼ 1) and injectable
dexamethasone (n¼ 1).Medications administered to
dogs in other groups included glucosamine, pro-
pentofylline, corticosteroids and non-steroidal anti-
inflammatory drugs. There was no significant dif-
ference in BP between the five groups (p¼0.197)
(Table 1). Thirteen group U patients were not
definitively diagnosed and therefore were excluded
from further statistical analysis. There was no sig-
nificant difference in serum creatinine concen-
tration between the four groups E, C, B and V
(Table 2). Two epileptic dogs had raised serum cre-
atinine concentrations (>150 mmol/L); however,
free catch urine samples obtained at blood sampling
Table 1 Signalment and collapse group assignment.
Total
n ¼ 79
E (epilepsy)
n ¼ 30
C (cardiogenic
syncope)
n ¼ 20
B (both heart
disease and
epilepsy) n ¼ 9
U (unclassified)
n ¼ 13
V (vasovagal)
n ¼ 7
p-Value
Age (years)
Median & range 5
0.3e15
3.9a,b
0.3e10.5
7.7a
0.8e15
4.5
0.8e12.3
8.8b,c
2e15
2c
0.7e9.5
p<0.001
Sex
Male n ¼ 42 n ¼ 16 n ¼ 11 n ¼ 4 n ¼ 7 n ¼ 4 p¼0.986
Female n ¼ 37 n ¼ 14 n ¼ 9 n ¼ 5 n ¼ 6 n ¼ 3
Reproductive status
Neutered n ¼ 53 n ¼ 19 n ¼ 15 n ¼ 6 n ¼ 11 n ¼ 2 p¼0.122
Entire n ¼ 26 n ¼ 11 n ¼ 5 n ¼ 3 n ¼ 2 n ¼ 5
Weight (kg)
Median & range 16.4
0.7e78.5
15.1
5.5e49.2
25
8.2e78.5
12.1
6.3e40
15.7
3.2e36
24.7
0.7e31.8
p¼0.258
Most commonly represented breeds p¼0.011
Boxer n ¼ 10 1 2 2 2 3
Cavalier King Charles spaniel n ¼ 9 2 1 4 2 e
Labrador retriever n ¼ 7 6 1 e e e
West Highland white terrier n ¼ 5 e 1 2 2 e
Border collie n ¼ 4 2 2 e e e
Cross breed n ¼ 4 1 2 e 1 e
Time since collapse (hours)
Median & range 48
0e168
n ¼ 78
42
0e168
26
2e168
48
8e144
72
4e168
n ¼ 12
120
48e168
p¼0.022
% Receiving medications at, or
shortly before, presentation
47%
37/79 n ¼ 79
60%
18/30
45%
9/20
56%
5/9
31%
4/13
14%
1/7
p¼0.163
Systolic BP (mmHg)
Mean & range
140
80e180
n ¼ 74
144
100e178
n ¼ 29
135
80e179
n ¼ 19
136
120e162
n ¼ 9
153
125e180
n ¼ 10
133
106e168
n ¼ 7
p¼0.197
Time from collapse to presentation, medications prescribed and systolic blood pressure on presentation, according to group.
Pairs sharing the same superscript (age) are significantly different from each other.
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Table 2 Serum cardiac troponin I (cTnI), and serum creatinine concentrations according to group, p value given.
Total n ¼ 66 E
n ¼ 30
C
n ¼ 20
B
n ¼ 9
V
n ¼ 7
p-Value # Animals above rr
Creatinine (mmol/L)
Mean & range 94
48e153
90
48e153
102
65e142
85
62e102
101
74e108
p¼0.132 n ¼ 2
cTnI (ng/mL)
Median & range 0.05
0.01e27.41
0.03a,b
0.01e1.92
0.165a,b
0.02e27.41
0.04
0.02e0.21
0.05b
0.01e0.08
p¼<0.001 n ¼ 24
E, epilepsy group; C, cardiogenic syncope group; B, both cardiac disease and epilepsy; V, vasovagal syncope group; rr, laboratory
reference range.
Pairs sharing the same superscript are significantly different from each other.
8 E. Dutton et al.were concentrated (USG >1.030). As both patients
had repeat blood tests at separate dates with crea-
tinine concentrations <150 mmol/L, the changes
were attributed to dehydration. Median cTnI values
were significantly different between the four groups
(Table 2). Overlap between groups was, however,
present. The epileptic patient with the highest
serum troponin concentration arrived in SE and
required GA for seizure control.
Univariable and multivariable linear regression
analysis were performed using the logarithmically
transformed data for cTnI (n ¼ 66). Univariable
results showed a strong association of log cTnI con-
centration with disease group (p<0.001), age
(p¼0.001) and time from collapse (p¼0.039). There
was no significant association with body weight
(p¼0.058), creatinine concentration (p¼0.065),
blood pressure (p¼0.19), neutered status (p¼0.24),Table 3 Results of the multivariable regression analysis.
Log cTnI Coefficient
Creatinine (mmol/L) 0.02
Groupa
B 1.46
E 1.97
V 1.50
On medication 0.48
Time from collapse 0.01
Constant 3.28
a Baseline level is C; Group E, epilepsy group; B, both cardiac d
Table 4 Sensitivity and specificity of classification for the
characteristic (ROC) curve area.
Groups cTnI cut-off
value
Correctly
classified
Sensitivity %
(95% CI)
Speci
(95
C vs. all other
except U
>0.08 ng/mL 78.8% 75 (51e91) 80 (6
C, cardiogenic syncope; U, unclassified; all other groups include c
a Prevalence ¼ 30.3% (calculated from this study).sex (p¼0.69) or whether on medication (p¼0.49).
The backwards stepwise regression retained crea-
tinine concentration (p¼0.028), disease group
(p<0.001), time from collapse (p¼0.015) and medi-
cation (p¼0.148; Table 3). The regression coef-
ficients indicated that cTnI increasedwith increasing
creatinine and with medication, whilst it decreased
with increasing time from collapse (p¼0.015).
Removal of medication from the final model had
little effect on the coefficients for the remaining two
variables, but the significance for group remained at
p<0.001, whereas that for creatinine changed to
p¼0.048. ROC analysis was used to estimate the
optimum cut-off value of serum cTnI concentrations
to discriminate between cardiac and non-cardiac
causes of collapse with TLOC. This provided a test
with a sensitivity of 75% and specificity of 80%; fur-
ther characteristics are shown in Table 4.p Value (95% Confidence interval)
0.028 (0.002 to 0.034)
<0.001
0.007 (2.51 to 0.41)
<0.001 (2.73 to 1.22)
0.014 (2.68 to 0.31)
0.148 (0.18 to 1.13)
0.015 (0.15 to 0.002)
0.002 (5.33 to 1.24)
isease and epilepsy; V, vasovagal syncope group.
serum cTnI cut-off values, including receiver operator
ficity %
% CI)
Positive
predictive value
(95% CI)
Negative
predictive value
(95% CI)
ROC Area
(95% CI)
6e91) 63%a (41e82) 88%a (74e96) 87% (76e94)
TnI, cardiac troponin I; CI, confidence interval.
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This study confirms that, as hypothesized, dogs
with cardiac syncope have higher cTnI concen-
trations than collapsing dogs with seizures and
other non-cardiac causes of collapse with TLOC. To
the authors’ knowledge, this is the first time this
has been shown in collapsing dogs. However, there
was overlap between the cardiac syncope and
seizure groups, so this biomarker is not discrim-
inatory. The results demonstrate that serum cTnI
concentrations are more markedly elevated in
cardiogenic syncope compared with non-cardiac
causes of collapse such as epilepsy. It would be
expected that there is greater myocardial injury in
dogs with cardiac disorders compared with dogs
with seizures. The majority of cardiogenic syncope
patients had arrhythmias, with a large proportion
having underlying structural heart disease. Possi-
ble mechanisms for troponin elevation in these
patients are numerous and include increased wall
stress causing subendocardial injury, effects of
neurohormones on myocytes, or tachyarrhythmias
causing reduced coronary perfusion. It is notable
that the two dogs with the highest troponin con-
centrations in group C had life-threatening ven-
tricular tachycardia. Neither had clinically
significant structural heart disease. Tests for
infectious causes of myocarditis were negative.
Unfortunately, both pets’ owners declined
abdominal ultrasound to help exclude systemic
disease as a cause of ventricular tachycardia,
although one patient was only 10 months old.
Of the group E dogs, those with the highest
serum cTnI concentrations had cluster seizures.
The patient with the highest serum troponin con-
centration arrived in SE, required GA for seizure
control and showed reversible ECG and echo-
cardiographic changes. Following treatment and,
whilst receiving anti-convulsants, a sinus brady-
cardia (60 beats/min) was recorded on ECG.
Echocardiography showed mild left ventricular
dilation, trivial mitral and tricuspid regurgitation,
but no structural valve abnormalities. The echo-
cardiographic changes seen were attributed to the
bradycardia. Repeat echocardiography performed
three weeks later in normal sinus rhythm
(120 beats/min) was unremarkable, indicating that
the changes were reversible. It is unclear whether
the changes detected were a result of anti-
epileptic medications or a direct result of the
cluster seizures.
The presence of myocardial injury with seizure
activity could be expected given the apnoea,
tachycardia, increased myocardial oxygenconsumption and excess catecholamine release
associated with seizures [41]. It has been
hypothesized that seizures may initiate an auto-
nomic storm which may have both para-
sympathetic and sympathetic effects [42]. This
may subsequently trigger cardiac dysrhythmias
and, in humans, sudden unexpected death in epi-
lepsy (SUDEP) [43]. Recent ECG studies show that
20% of human patients experience abnormally slow
heart rates during seizures, culminating in 16%
with asystole [43]. This may be due to brainstem
autonomic dysfunction of parasympathetic outflow
leading to sinus and AV nodal block. Another
hypothesis is that some epileptic patients have
brain and cardiac ion channelopathies [43]. In
human patients, bradyarrhythmias are mostly
associated with temporal lobe seizures [44].
Cortical stimulation of the left insular cortex and
amygdalae can also elicit bradycardias [45].
There are a few publications reporting
increased circulating cTnI concentrations following
GA in healthy dogs, with older dogs seemingly
being more affected [46,47]. Overall, 14e55% of
the dogs were reported as having increased cTnI
concentrations posteGA, with variations in sam-
pling ranging from 6 to 24 h after discontinuation
of GA [46,47]. Some dogs were reported as having
cTnI concentrations which decreased following GA
[46,47], whereas one study reported no significant
difference following GA [48]. In this study, only
one SE patient required GA for seizure control in
which cTnI sampling was delayed until 24 h fol-
lowing GA. This same patient had the highest
serum cTnI concentration in group E. It is possible
that the GA affected serum cTnI concentrations,
resulting in elevated concentrations. However,
two other group E patients with cluster seizures
also had elevated cTnI concentrations (according
to the laboratory reference range) despite not
requiring GA for seizure control. Elevated cTnI
concentrations may be due to cardiac necrosis
lesions, caused by catecholamines released
directly into the heart of the dogs with cluster
seizures via neural connections. Catecholamines
released directly into the myocardium are more
toxic than those reaching the heart via blood-
stream [42]. Further studies involving larger num-
bers of patients with cluster seizures, pre- and
posteGA, would be required to further investigate
this association with serum cTnI concentrations.
In group V, the five suspected vasovagal patients
did not collapse wearing the Holter monitor but
had a consistent history or were typical breeds
(brachycephalic). This highlights the challenge
faced obtaining a definitive diagnosis in patients
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the low diagnostic yield of Holter analysis; in one
study only 24% of the patients collapsed during the
Holter recording [12]. The recording was helpful in
establishing a diagnosis 42% of the time [12]. The
five patients with suspected vasovagal syncope
were included in group V, despite not being
definitively diagnosed as there was no clear evi-
dence of any cardiac, metabolic or neurological
disease which could have contributed to the col-
lapse. They were mainly typical breeds (one boxer,
one pug, one English bull terrier), had evidence on
a Holter recording of a rapid transition from sinus
rhythm to sinus bradycardia (n ¼ 1) during a
stumbling episode (but did not collapse), or had
the typical history, i.e. brief collapse following
intense excitement with rapid recovery (n ¼ 5).
These cases were not excluded from the analysis
due to the strong suspicion by the attending
clinician that they were indeed collapsing due to
vasovagal syncope. In group B, all the dogs col-
lapsed due to seizures and many had incidental
mitral valve disease. Having an unclassified group
(group U) was expected given the intermittent
nature of collapse. It has been shown previously
that definitively diagnosing collapse in dogs
remains challenging. However, most dogs with
collapse of an unknown cause carry a good prog-
nosis, with the exception of boxers, possibly due to
the presence of concurrent disease (e.g. arrhyth-
mogenic right ventricular cardiomyopathy or neo-
plastic disease) [2,49,50].
Disease group and time from collapse to blood
sampling were independently associated with cTnI
concentrations. Time from collapse to blood sam-
pling was negatively associated with cTnI concen-
tration in all groups, reflecting the release kinetics
and elimination of troponin. It illustrates the
importance of inclusion criteria and highlights that
the results of this study are only valid if clinicians
collect cTnI serum within seven days following
collapse. In this study, the time between the col-
lapse episode and blood sampling varied. Consid-
ering the release kinetics of troponin, it is possible
that peak circulating troponin concentrations were
missed, particularly in patients presenting days
after collapsing. Serial troponin measurements,
commencing immediately after collapsing would
have been preferable and might have shown
improved diagnostic accuracy.
Serum creatinine was positively and independ-
ently associated with cTnI concentration. This was
a particularly interesting finding as patients with
renal insufficiency (creatinine concentrations
>150 mmol/L and USG <1.030) were excluded. To
the authors’ knowledge, this relationship betweencTnI and creatinine concentration has not been
previously reported in patients without evidence
of renal insufficiency. If further studies confirm
this as a true association, its cause is unclear. It
may be due to troponin possibly being eliminated
by the renal system, or perhaps due to subclinical
myocardial damage rather than altered excretion.
In dogs with renal dysfunction, it has previously
been shown that circulating cTnI concentrations
are increased [17,18]. Subclinical myocardial
damage may include direct myocardial injury
caused by uremic toxins [51].
Inspection of the ROC curve indicates assay
sensitivity and specificity at any given cut-off
value and the ROC analysis for distinguishing
between the cardiac and non-cardiac groups gave
an area under curve of 0.87. This would suggest
that the biomarker may help discriminate cardio-
genic syncope from non-cardiac causes of collapse,
such as epileptic seizures. This could be useful
considering how the various clinical situations
mimic one another. However, inspection of the
cTnI values shows overlap between groups C and
groups B, E and V, suggesting that the test should
not be used alone. Of the 30 dogs with seizures,
five have raised cTnI concentrations according to
laboratory reference range and also using the
optimal cut-off value of 0.08 ng/mL (Tables 2 and
4). Three of these patients should be easily iden-
tified as epileptic on history alone, due to the
presence of cluster seizures. At the same cut-off
(0.08 ng/mL), of the 20 group C patients, 15 are
correctly classified (true positives), leaving five
group C patients undetected, despite having car-
diac causes of syncope (false negatives). This
highlights a limitation of the test (i.e. limited
sensitivity and specificity) and means that meas-
urement of serum cTnI concentration should not
be the sole test used for diagnosing dogs with
cardiogenic syncope. However, it may assist prac-
titioners, in conjunction with other cardiac inves-
tigations such as ECG, to help differentiate
cardiogenic syncope from dogs with generalized
seizures or vasovagal syncope. A low (<0.08 ng/
mL) cTnI concentration may help exclude a car-
diogenic cause of syncope.
There are numerous limitations with this study,
intrinsic to clinical studies. Idiopathic epilepsy is a
diagnosis of exclusion. Some dogs with seizures
may have been incorrectly classified. Two epi-
leptic dogs had MRI evidence of brain tumours;
however, no post-mortem examinations were
performed. All but one dog underwent a full car-
diac evaluation which eliminated significant car-
diac disease as a cause of troponin elevation in the
non-cardiac groups. The group E patient which had
Cardiac troponin in syncope and seizures 11no cardiac investigations had no auscultatory
abnormalities and troponin concentrations were
within the laboratory reference range. As systemic
disease of non-cardiac origin, especially inflam-
matory, neoplastic and renal disease also fre-
quently leads to elevated cTnI concentrations,
excluding patients with such diseases based on
history, examination and blood tests was an
important component of this study. No patients
had myocardial biopsies or post-mortem examina-
tions to confirm myocardial cellular damage. Most
study cases had a history of collapse, yet the direct
effect of blunt chest trauma on troponin release
was not taken into account. The act of collapsing,
particularly if during high intensity exercise, could
conceivably result in thoracic trauma, and trauma
can cause troponin release [52,53]. However,
other than the collapse itself, no dog in this study
had a history of trauma.
Some group sizes are small, affecting the power
of the statistical analyses. It is possible that some
patients were misclassified according to their group
categorization, e.g. only two group V dogs were
definitively diagnosed as having the cardio-
inhibitory form of vasovagal collapse. Small
patient numbers in group C (n¼ 20) with a variety of
underlying disease processes may reduce the over-
all significance of the results. Effect of neoplasia in
group C was not examined, with four patients hav-
ing neoplastic involvement. The series of patients
presented here represent a referral population
which may differ from the general practice canine
population. Effect of breed was not assessed due to
small numbers and diverse breeds.
The results of this study only apply to the tro-
ponin analyser used [34]. The influence of daily
variation on biomarker concentration and effect of
storage conditions on troponin stability were not
assessed. However, all blood samples were stored
and handled in a careful, easily reproducible,
consistent manner to minimize analytical issues.Conclusions
Patients collapsing with a cardiac cause have sig-
nificantly increased troponin concentrations com-
pared with epileptic or vasovagal patients;
however, the overlap in troponin concentrations
reduces the discriminatory power of the test in an
individual dog. Therefore, troponin assays should
not be used as stand-alone tests, but in combination
with other diagnostic investigations, such as ECG
and echocardiography. Future large prospective
studies investigating the possible prognostic value
of cTnI in syncopal dogs are warranted.Conflicts of Interest
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